Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2024 | 805 | 1.760 |
Why?
|
| Methotrexate | 7 | 2024 | 341 | 1.580 |
Why?
|
| Rhabdomyosarcoma | 2 | 2025 | 200 | 0.960 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2024 | 29 | 0.800 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.740 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2024 | 178 | 0.690 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2024 | 48 | 0.650 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1439 | 0.560 |
Why?
|
| Bayes Theorem | 3 | 2023 | 278 | 0.410 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 131 | 0.380 |
Why?
|
| Child | 17 | 2025 | 24226 | 0.340 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.240 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 35 | 0.240 |
Why?
|
| Creatinine | 2 | 2023 | 380 | 0.230 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2024 | 49 | 0.230 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.230 |
Why?
|
| Constipation | 1 | 2024 | 112 | 0.220 |
Why?
|
| Prognosis | 4 | 2025 | 4513 | 0.220 |
Why?
|
| von Willebrand Diseases | 1 | 2023 | 50 | 0.210 |
Why?
|
| Adolescent | 10 | 2025 | 19096 | 0.210 |
Why?
|
| Health Information Systems | 1 | 2022 | 32 | 0.200 |
Why?
|
| Warfarin | 1 | 2023 | 118 | 0.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 54 | 0.200 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2022 | 22 | 0.200 |
Why?
|
| Precision Medicine | 1 | 2025 | 305 | 0.190 |
Why?
|
| von Willebrand Factor | 1 | 2023 | 197 | 0.190 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 51 | 0.190 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 70 | 0.190 |
Why?
|
| Wilms Tumor | 1 | 2023 | 111 | 0.190 |
Why?
|
| Child, Preschool | 6 | 2025 | 13881 | 0.180 |
Why?
|
| Hemorrhage | 1 | 2023 | 458 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2022 | 233 | 0.170 |
Why?
|
| Humans | 19 | 2025 | 123070 | 0.160 |
Why?
|
| Cross Infection | 1 | 2022 | 330 | 0.160 |
Why?
|
| Infant | 5 | 2025 | 12355 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2024 | 626 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 432 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 111 | 0.150 |
Why?
|
| Risk Factors | 2 | 2023 | 10016 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 234 | 0.150 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1386 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 198 | 0.140 |
Why?
|
| Aortic Diseases | 1 | 2019 | 197 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1200 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2024 | 16039 | 0.120 |
Why?
|
| Age Factors | 1 | 2021 | 2803 | 0.120 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 520 | 0.110 |
Why?
|
| Thrombosis | 1 | 2019 | 520 | 0.110 |
Why?
|
| Male | 7 | 2025 | 60080 | 0.100 |
Why?
|
| Female | 7 | 2025 | 65529 | 0.090 |
Why?
|
| Mutation | 1 | 2025 | 5765 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2024 | 581 | 0.080 |
Why?
|
| Incidence | 2 | 2024 | 3044 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 5048 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 17 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2024 | 169 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 183 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 42 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 96 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 62 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2022 | 79 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 46 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2023 | 301 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 172 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 102 | 0.050 |
Why?
|
| Malawi | 1 | 2023 | 389 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 924 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1161 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 8837 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 578 | 0.040 |
Why?
|
| Heart Rate | 1 | 2022 | 586 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1238 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1213 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1305 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 477 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 197 | 0.040 |
Why?
|
| Survival Rate | 1 | 2022 | 1997 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 204 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1118 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1232 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 4703 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1049 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1876 | 0.030 |
Why?
|
| Time Factors | 1 | 2022 | 6222 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3544 | 0.020 |
Why?
|
| United States | 1 | 2022 | 10651 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 12123 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8109 | 0.020 |
Why?
|
| Adult | 1 | 2022 | 29011 | 0.010 |
Why?
|